Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review

被引：0
|
作者：
Wang, Wei [1 ,2 ]
Wu, Jiayi [1 ,3 ]
Chen, Keyu [1 ,3 ]
Wang, Xiaojia [1 ]
Shao, Xiying [1 ]
机构：
[1] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol,Breast Canc, 1 Banshandong Rd, Hangzhou, Peoples R China
[2] Wenzhou Med Univ, Dept Clin Med, Wenzhou, Peoples R China
[3] Zhejiang Chinese Med Univ, Dept Clin Med, Hangzhou, Peoples R China
来源：
TECHNOLOGY IN CANCER RESEARCH & TREATMENT | 2023年 / 22卷
关键词：
breast cancer; palbociclib; CDK4; 6; inhibitor; prognostic parameters; LETROZOLE;
D O I：
10.1177/15330338231173504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recent studies have demonstrated that the combination of Cyclin-Dependent Kinase 4/6 Inhibitor (CDK4/6i) and endocrine therapy (ET) is more effective than ET alone and significantly improves progression-free survival (PFS) and overall survival (OS) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) breast cancer (BC). Palbociclib is the first CDK4/6i approved for use, and its clinical advantages have been shown. However, 30% of patients will continue to develop secondary drug resistance. Therefore, exploring the parameters that can predict the efficacy of Palbociclib and developing a clinical prediction model is essential for evaluating the prognosis of patients.
引用
收藏
页数：9
相关论文
共 50 条
  • [21] Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS study
    Mycock, Katie
    Zhan, Lin
    Hart, Kieran
    Taylor-Stokes, Gavin
    Milligan, Gary
    Atkinson, Christian
    Mitra, Debanjali
    FUTURE ONCOLOGY, 2021, 18 (03) : 349 - 362
  • [22] Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2-Advanced Breast Cancer
    Dieras, Veronique
    Rugo, Hope S.
    Schnell, Patrick
    Gelmon, Karen
    Cristofanilli, Massimo
    Loi, Sherene
    Colleoni, Marco
    Lu, Dongrui R.
    Mori, Ave
    Gauthier, Eric
    Huang Bartlett, Cynthia
    Slamon, Dennis J.
    Turner, Nicholas C.
    Finn, Richard S.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2019, 111 (04): : 419 - 430
  • [23] PATIENT REPORTED HEALTH UTILITY IN HR+/HER2-ADVANCED/METASTATIC BREAST CANCER
    Mitra, D.
    Wood, R.
    De Courcy, J.
    Iyer, S.
    VALUE IN HEALTH, 2016, 19 (07) : A749 - A749
  • [24] Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2-Advanced Breast Cancer
    Stellato, Daniel
    Thabane, Marroon
    Eichten, Caitlin
    Delea, Thomas E.
    CURRENT ONCOLOGY, 2021, 28 (01) : 491 - 508
  • [25] NETWORK META-ANALYSIS COMPARING PALBOCICLIB WITH CHEMOTHERAPIES FOR TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR+/ HER2-ADVANCED/METASTATIC BREAST CANCER
    Wilson, F. R.
    Varu, A.
    Mitra, D.
    Cameron, C.
    Iyer, S.
    VALUE IN HEALTH, 2016, 19 (07) : A714 - A714
  • [26] Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2-advanced breast cancer
    Bardia, A.
    Modi, S.
    Oliveira, M.
    Campone, M.
    Ma, B.
    Dirix, L.
    Weise, A.
    Nardi, L.
    Zhang, V.
    Bhansali, S. G.
    Hewes, B.
    Chavez-MacGregor, M.
    CANCER RESEARCH, 2016, 76
  • [27] MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2-advanced breast cancer
    Di Leo, A.
    Toi, M.
    Campone, M.
    Sohn, J.
    Paluch-Shimon, S.
    Huober, J.
    Park, I. H.
    Tredan, O.
    Chen, S-C.
    Manso, L.
    Freedman, O.
    Jaliffe, G. G.
    Forrester, T.
    Frenzel, M.
    Barriga, S.
    Smith, I. C.
    Bourayou, N.
    Goetz, M. P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] Ribociclib for post-menopausal women with HR+/HER2-advanced or metastatic breast cancer
    Zangardi, Mark L.
    Spring, Laura M.
    Blouin, Gayle C.
    Bardia, Aditya
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (11) : 1169 - 1176
  • [29] Ribociclib plus fulvestrant in postmenopausal women with HR+, HER2-advanced breast cancer (ABC)
    Tolaney, S. M.
    Forero-Torres, A.
    Boni, V.
    Bachelot, T.
    Lu, Y-S
    Maur, M.
    Fasolo, A.
    Motta, M.
    Pan, C.
    Dobson, J.
    Hewes, B.
    Lee, S. Chin
    CANCER RESEARCH, 2017, 77
  • [30] MONARCH 3: Abemaciclib as Initial Therapy for Patients with HR+/HER2-Advanced Breast Cancer
    Leo, A. D.
    Toi, M.
    Campone, M.
    Sohn, J. H.
    Shimon, S. P.
    Huober, J.
    Park, I. H.
    Tredan, O.
    Chen, S. -C.
    Manso, L.
    Freedman, O.
    Jaliffe, G. G.
    Forrester, T. D.
    Frenzel, M.
    Barriga, S.
    Smith, I. C.
    Bourayou, N.
    Goetz, M. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 5 - 5
12345